Lattice_grid_med
Powered by LatticeGrid

Search Enter term and hit return. Use '*' for as a wildcard.

Publication Listing for the MeSH term radical prostatectomy. Found 43 abstracts

no pagination
Ristau BT, Cahn D, Uzzo RG, Chapin BF, Smaldone MC. The role of radical prostatectomy in high-risk localized, node-positive and metastatic prostate cancer. Future Oncol. 2016 Mar;12(5):687-99.   PMCID: Review
Buyyounouski MK, Pickles T, Kestin LL, Allison R, Williams SG. Validating the Interval to Biochemical Failure for the Identification of Potentially Lethal Prostate Cancer. Journal of Clinical Oncology. 2012 May;30(15):1857-63.   PMCID: not NIH funded
Klayton T, Price R, Buyyounouski MK, Sobczak M, Greenberg R, Li JS, Keller L, Sopka D, Kutikov A, Horwitz EM. Prostate Bed Motion During Intensity-Modulated Radiotherapy Treatment. International Journal of Radiation Oncology Biology Physics. 2012 Sep;84(1):130-6.   PMCID: PMC3285397
Kutikov A, Cooperberg MR, Paciorek AT, Uzzo RG, Carroll PR, Boorjian SA. Evaluating prostate cancer mortality and competing risks of death in patients with localized prostate cancer using a comprehensive nomogram. Prostate Cancer and Prostatic Diseases. 2012 Dec;15(4):374-9.   PMCID: Not NIH fund
Lubbe W, Cohen R, Sharma N, Ruth K, Peters R, Li JS, Buyyounouski M, Kutikov A, Chen D, Uzzo R, Horwitz E. Biochemical and clinical experience with real-time intraoperatively planned permanent prostate brachytherapy. Brachytherapy. 2012 May;11(3):209-13.
Zaorsky NG, Li TY, Devarajan K, Horwitz EM, Buyyounouski MK. Assessment of the American Joint Committee on Cancer Staging (Sixth and Seventh Editions) for Clinically Localized Prostate Cancer Treated With External Beam Radiotherapy and Comparison With the National Comprehensive Cancer Network Risk-Stratification Method. Cancer. 2012 Nov;118(22):5535-43.   PMCID: PMC3410044
Rodrigues G, Bae K, Roach M, Lawton C, Donnelly B, Grignon D, Hanks G, Porter A, Lepor H, Sandler H. IMPACT OF ULTRAHIGH BASELINE PSA LEVELS ON BIOCHEMICAL AND CLINICAL OUTCOMES IN TWO RADIATION THERAPY ONCOLOGY GROUP PROSTATE CLINICAL TRIALS. International Journal of Radiation Oncology Biology Physics. 2011 Jun;80(2):445-52.   PMCID: PMC2952349
Rosenthal SA, Bittner NH, Beyer DC, Demanes DJ, Goldsmith BJ, Horwitz EM, Ibbott GS, Lee WR, Nag S, Suh WW, Potters L. AMERICAN SOCIETY FOR RADIATION ONCOLOGY (ASTRO) AND AMERICAN COLLEGE OF RADIOLOGY (ACR) PRACTICE GUIDELINE FOR THE TRANSPERINEAL PERMANENT BRACHYTHERAPY OF PROSTATE CANCER. International Journal of Radiation Oncology Biology Physics. 2011 Feb;79(2):335-41.   PMCID: PMCID: PMC3030655 [Available on 2012/2/1]
Michalski JM, Lawton C, El Naqa I, Ritter M, O'Meara E, Seider MJ, Lee WR, Rosenthal SA, Pisansky T, Catton C, Valicenti RK, Zietman AL, Bosch WR, Sandler H, Buyyounouski MK, Menard C. Development of RTOG consensus guidelines for the definition of the clinical target volume for postoperative conformal radation therapy for prostate cancer. International Journal of Radiation Oncology Biology Physics. 2010 Feb;76(2):361-8.   PMCID: PMC2847420
Roach M, Bae K, Lawton C, Donnelly BJ, Grignon D, Hanks GE, Porter A, Lepor H, Venketesan V, Sandler H. BASELINE SERUM TESTOSTERONE IN MEN TREATED WITH ANDROGEN DEPRIVATION THERAPY AND RADIOTHERAPY FOR LOCALIZED PROSTATE CANCER. International Journal of Radiation Oncology Biology Physics. 2010 Dec;78(5):1314-22.   PMCID: PMCID: PMC2920356 [Available on 2011/12/1]
Ray ME, Bae K, Hussain MH, Hanks GE, Shipley WU, Sandler HM. Potential Surrogate Endpoints for Prostate Cancer Survival: Analysis of a Phase III Randomized Trial. Journal of the National Cancer Institute. 2009 Feb;101(4):228-36.   PMCID: PMC2734115
Khor LY, DeSilvio M, Li RL, McDonnell TJ, Hammond ME, Sause WT, Pilepich MV, Okunieff P, Sandler HM, Pollack A. Bcl-2 and bax expression and prostate cancer outcome in men treated with radiotherapy in Radiation Therapy Oncology Group protocol 86-10. INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS. 2006 Sep;66(1):25-30.
Kuban DA, Levy LB, Potters L, Beyer DC, Blasko JC, Moran BJ, Ciezki JP, Zietman AL, Zelefsky MJ, Pisansky TM, Elshaikh M, Horwitz EM. Comparison of biochemical failure definitions for permanent prostate brachytherapy. INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS. 2006 Aug;65(5):1487-93.
Roach M, Hanks G, Thames H, Schellhammer P, Shipley WU, Sokol GH, Sandler H. Defining biochemical failure following radiotherapy with or without hormonal therapy in men with clinically localized prostate cancer: Recommendations of the RTOG-ASTRO Phoenix Consensus Conference. INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS. 2006 Jul;65(4):965-74.
Andrews SF, Horwitz EM, Feigenberg SJ, Eisenberg DF, Hanlon AL, Uzzo RG, Pollack A. Does a delay in external beam radiation therapy after tissue diagnosis affect outcome for men with prostate carcinoma?. Cancer. 2005 Jul 15;104(2):299-304.
Feigenberg SJ, Hanlon AL, Horwitz EM, Uzzo RG, Eisenberg DF, Pollack A. What pretreatment prostate-specific antigen level warrants long-term androgen deprivation?. International Journal of Radiation Oncology Biology Physics. 2005 Mar 15;61(4):1003-10.
Hayes SB, Pollack A. Parameters for treatment decisions for salvage radiation therapy. Journal of Clinical Oncology. 2005 Nov 10;23(32):8204-11.
Horwitz EM, Thames HD, Kuban DA, Levy LB, Kupelian PA, Martinez AA, Michalski JM, Pisansky TM, Sandler HM, Shipley WU, Zelefsky MJ, Hanks GE, Zietman AL. Definitions of biochemical failure that best predict clinical failure in patients with prostate cancer treated with external beam radiation alone: A multi-institutional pooled analysis. Journal of Urology. 2005 Mar;173(3):797-802.
Kupelian P, Kuban D, Thames H, Levy L, Horwitz E, Martinez A, Michalski J, Pisansky T, Sandler H, Shipley W, Zelefsky M, Zietman A. Improved biochemical relapse-free survival with increased external radiation doses in patients with localized prostate cancer: The combined experience of nine institutions in patients treated in 1994 and 1995. International Journal of Radiation Oncology Biology Physics. 2005 Feb;61(2):415-9.
Kupelian P, Thames H, Levy L, Horwitz E, Martinez A, Michalski J, Pisansky T, Sandler H, Shipley W, Zelefsky M, Zietman A, Kuban D. Year of treatment as independent predictor of relapse-free survival in patients with localized prostate cancer treated with definitive radiotherapy in the PSA era. International Journal of Radiation Oncology Biology Physics. 2005 Nov;63(3):795-9.
The above publications are sorted by year, faculty last name, and first author. Click on any highlighted author listed to find all publications attributed to that individual. Click on the publication title to see the abstract. First authors who are faculty are highlighted like this. Last authors who are faculty are highlighted like this. Other authors who are faculty are highlighted like this.

MeSH cloud from publications including the MeSH term radical prostatectomy

radical prostatectomy radiotherapy radiation-therapy external-beam radiotherapy phase-iii trial follow-up outcomes men prostate-specific antigen prostate cancer gleason score Oncology Prostate cancer androgen suppression cancer seed implantation carcinoma androgen deprivation Nuclear Medicine & Medical Imaging Radiology biochemical failure local recurrence iii randomized trial Clinical trials prostatic neoplasms predict pathological stage experience failure dose-response free survival Prognostic factors conformal radiation-therapy adjuvant therapy brachytherapy prostate progression Dosimetry recommendations External beam radiation therapy radiation therapy radical prostatectomy-nomogram-competing risks-comorbidities psa doubling time risk implant postprostatectomy radiotherapy impact therapy oncology group comorbidity apoptosis definitions randomized multicenter trial hypogonadal men three-dimensional conformal radiotherapy PSA Serum testosterone ki-67 recursive partitioning analysis escalation adjuvant radiotherapy radiation dose level antigen era trial cytoreductive surgery Outcomes staging prostate cancer-radiotherapy-American Joint Committee on Cancer-National Comprehensive Cancer Network cancer patients postoperative radiotherapy imrt conformal radiotherapy gland neoadjuvant hormonal-therapy competing risk radiation therapy prostate carcinoma-treatment delay antigen candidates antigen doubling time localized prostate cancer gy oncology consensus definition external-beam radiation assessing biochemical failure radiation therapy american-society i-125 brachytherapy surrogate end-point surgery toxicity year of therapy radiation greater-than-20 algorithm bax conference positron-emission-tomography antigen bounce system psa interstitial brachytherapy colon-cancer prognostic-significance hormonal-therapy immunohistochemical analysis Safety ml Postoperative Androgen deprivation therapy clinical-practice dosimetry therapy androgen-deprivation therapy ng accuracy p53 Hormonal therapy stage migration american society biochemical recurrence locally advanced-carcinoma interval survival psa velocity interobserver variability replacement therapy Radiation therapy relapse-free survival localization deprivation consensus management adjuvant androgen ablation pathological stage Quality Assurance competing biopsy cores prognostic-factors group protocol 92-02 biochemical relapse-free survival neoadjuvant Brachytherapy Prostate cancer-Implant-Small-volume prostate size coil Target volumes Motion Localization-Postprostatectomy-Tracking androgen ablation beam radiotherapy Prostate Cancer nerve-sparing prostatectomy PSA failure Bcl-2 survival outcomes in-vivo irradiation
Last updated on Sunday, July 12, 2020